当前位置: 首页 >> 检索结果
681. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial.
作者: Frederik Dalgaard.;Hillary Mulder.;Daniel M Wojdyla.;Renato D Lopes.;Claes Held.;John H Alexander.;Raffaele De Caterina.;Jeffrey B Washam.;Elaine M Hylek.;David A Garcia.;Bernard J Gersh.;Lars Wallentin.;Christopher B Granger.;Sana M Al-Khatib.
来源: Circulation. 2020年141卷1期10-20页
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) with oral anticoagulants has been associated with an increased risk of bleeding. We investigated the risk of bleeding and major cardiovascular outcomes in patients with atrial fibrillation taking NSAIDs and apixaban or warfarin.
682. Results of the FUEL Trial.
作者: David J Goldberg.;Victor Zak.;Bryan H Goldstein.;Kurt R Schumacher.;Jonathan Rhodes.;Daniel J Penny.;Christopher J Petit.;Salil Ginde.;Shaji C Menon.;Seong-Ho Kim.;Gi Beom Kim.;Todd T Nowlen.;Michael V DiMaria.;Benjamin P Frischhertz.;Jonathan B Wagner.;Kimberly E McHugh.;Brian W McCrindle.;Amanda J Shillingford.;Arash A Sabati.;Anji T Yetman.;Anitha S John.;Marc E Richmond.;Matthew D Files.;R Mark Payne.;Andrew S Mackie.;Christopher K Davis.;Shabana Shahanavaz.;Kevin D Hill.;Ruchira Garg.;Jeffrey P Jacobs.;Michelle S Hamstra.;Stacy Woyciechowski.;Kathleen A Rathge.;Michael G McBride.;Peter C Frommelt.;Mark W Russell.;Elaine M Urbina.;James L Yeager.;Victoria L Pemberton.;Mario P Stylianou.;Gail D Pearson.;Stephen M Paridon.; .
来源: Circulation. 2020年141卷8期641-651页
The Fontan operation creates a total cavopulmonary connection, a circulation in which the importance of pulmonary vascular resistance is magnified. Over time, this circulation leads to deterioration of cardiovascular efficiency associated with a decline in exercise performance. Rigorous clinical trials aimed at improving physiology and guiding pharmacotherapy are lacking.
683. Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement: A Propensity-Matched Comparison From the FRANCE-TAVI Registry.
作者: Eric Van Belle.;Flavien Vincent.;Julien Labreuche.;Vincent Auffret.;Nicolas Debry.;Thierry Lefèvre.;Helene Eltchaninoff.;Thibaut Manigold.;Martine Gilard.;Jean-Phillipe Verhoye.;Dominique Himbert.;Rene Koning.;Jean-Phillipe Collet.;Pascal Leprince.;Emmanuel Teiger.;Alain Duhamel.;Alessandro Cosenza.;Guillaume Schurtz.;Sina Porouchani.;Benoit Lattuca.;Emmanuel Robin.;Augustin Coisne.;Thomas Modine.;Marjorie Richardson.;Patrick Joly.;Gilles Rioufol.;Said Ghostine.;Olivier Bar.;Nicolas Amabile.;Didier Champagnac.;Patrick Ohlmann.;Nicolas Meneveau.;Thibaut Lhermusier.;Lionel Leroux.;Florence Leclercq.;Thomas Gandet.;Frédéric Pinaud.;Thomas Cuisset.;Pascal Motreff.;Géraud Souteyrand.;Bernard Iung.;Thierry Folliguet.;Philippe Commeau.;Guillaume Cayla.;Gilles Bayet.;Olivier Darremont.;Christian Spaulding.;Hervé Le Breton.;Cédric Delhaye.
来源: Circulation. 2020年141卷4期243-259页
No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date.
684. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
作者: Mikhail N Kosiborod.;Pardeep S Jhund.;Kieran F Docherty.;Mirta Diez.;Mark C Petrie.;Subodh Verma.;Jose C Nicolau.;Béla Merkely.;Masafumi Kitakaze.;David L DeMets.;Silvio E Inzucchi.;Lars Køber.;Felipe A Martinez.;Piotr Ponikowski.;Marc S Sabatine.;Scott D Solomon.;Olof Bengtsson.;Daniel Lindholm.;Anna Niklasson.;Mikaela Sjöstrand.;Anna Maria Langkilde.;John J V McMurray.
来源: Circulation. 2020年141卷2期90-99页
Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin on a broad range of health status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ).
685. Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis: Data From a Nationwide Analysis.
作者: Pierre Deharo.;Arnaud Bisson.;Julien Herbert.;Thibaud Lacour.;Christophe Saint Etienne.;Leslie Grammatico-Guillon.;Alizée Porto.;Frederic Collart.;Thierry Bourguignon.;Thomas Cuisset.;Laurent Fauchier.
来源: Circulation. 2020年141卷4期260-268页
Two competing transcatheter aortic valve replacement (TAVR) technologies are currently available. Head-to-head comparisons of the relative performances of these 2 devices have been published. However, long-term clinical outcome evaluation remains limited by the number of patients analyzed, in particular, for recent-generation devices.
686. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
作者: Felipe A Martinez.;Matteo Serenelli.;Jose C Nicolau.;Mark C Petrie.;Chern-En Chiang.;Sergey Tereshchenko.;Scott D Solomon.;Silvio E Inzucchi.;Lars Køber.;Mikhail N Kosiborod.;Piotr Ponikowski.;Marc S Sabatine.;David L DeMets.;Monika Dutkiewicz-Piasecka.;Olof Bengtsson.;Mikaela Sjöstrand.;Anna Maria Langkilde.;Pardeep S Jhund.;John J V McMurray.
来源: Circulation. 2020年141卷2期100-111页
The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies reduced the risk of mortality and heart failure hospitalization and improved symptoms in patients with heart failure and reduced ejection fraction. We examined the effects of dapagliflozin according to age, given potential concerns about the efficacy and safety of therapies in the elderly.
687. Aerobic Exercise Induces Cardiac Fat Loss and Alters Cardiac Muscle Mass Through an Interleukin-6 Receptor-Dependent Mechanism: Cardiac Analysis of a Double-Blind Randomized Controlled Clinical Trial in Abdominally Obese Humans.
作者: Regitse Højgaard Christensen.;Louise Lang Lehrskov.;Anne-Sophie Wedell-Neergaard.;Grit Elster Legaard.;Mathias Ried-Larsen.;Kristian Karstoft.;Rikke Krogh-Madsen.;Bente Klarlund Pedersen.;Helga Ellingsgaard.;Jaya Birgitte Rosenmeier.
来源: Circulation. 2019年140卷20期1684-1686页 688. Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure.
作者: Luc Djoussé.;Nancy R Cook.;Eunjung Kim.;Vijaykumar Bodar.;Joseph Walter.;Vadim Bubes.;Heike Luttmann-Gibson.;Samia Mora.;Jacob Joseph.;I-Min Lee.;Christine M Albert.;Julie E Buring.;J Michael Gaziano.;JoAnn E Manson.; .
来源: Circulation. 2020年141卷9期784-786页 689. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study.
作者: Paolo Raggi.;Antonio Bellasi.;David Bushinsky.;Jordi Bover.;Mariano Rodriguez.;Markus Ketteler.;Smeeta Sinha.;Carolina Salcedo.;Kristen Gillotti.;Claire Padgett.;Rekha Garg.;Alex Gold.;Joan Perelló.;Glenn M Chertow.
来源: Circulation. 2020年141卷9期728-739页
The high cardiovascular morbidity and mortality in patients with end-stage kidney disease could be partially caused by extensive cardiovascular calcification. SNF472, intravenous myo-inositol hexaphosphate, selectively inhibits the formation and growth of hydroxyapatite.
690. Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
作者: Nicholas A Marston.;Frederick K Kamanu.;Francesco Nordio.;Yared Gurmu.;Carolina Roselli.;Peter S Sever.;Terje R Pedersen.;Anthony C Keech.;Huei Wang.;Armando Lira Pineda.;Robert P Giugliano.;Steven A Lubitz.;Patrick T Ellinor.;Marc S Sabatine.;Christian T Ruff.
来源: Circulation. 2020年141卷8期616-623页
The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established.
691. Coronary Microvascular Dysfunction Is Associated With Myocardial Ischemia and Abnormal Coronary Perfusion During Exercise.
作者: Haseeb Rahman.;Matthew Ryan.;Matthew Lumley.;Bhavik Modi.;Hannah McConkey.;Howard Ellis.;Cian Scannell.;Brian Clapp.;Michael Marber.;Andrew Webb.;Amedeo Chiribiri.;Divaka Perera.
来源: Circulation. 2019年140卷22期1805-1816页
Coronary microvascular dysfunction (MVD) is defined by impaired flow augmentation in response to a pharmacological vasodilator in the presence of nonobstructive coronary artery disease. It is unknown whether diminished coronary vasodilator response correlates with abnormal exercise physiology or inducible myocardial ischemia.
692. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.
作者: Renato D Lopes.;Sergio Leonardi.;Daniel M Wojdyla.;Amit N Vora.;Laine Thomas.;Robert F Storey.;Dragos Vinereanu.;Christopher B Granger.;Shaun G Goodman.;Ronald Aronson.;Stephan Windecker.;Holger Thiele.;Marco Valgimigli.;Roxana Mehran.;John H Alexander.
来源: Circulation. 2020年141卷9期781-783页 693. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
作者: Amy Damask.;P Gabriel Steg.;Gregory G Schwartz.;Michael Szarek.;Emil Hagström.;Lina Badimon.;M John Chapman.;Catherine Boileau.;Sotirios Tsimikas.;Henry N Ginsberg.;Poulabi Banerjee.;Garen Manvelian.;Robert Pordy.;Sibylle Hess.;John D Overton.;Luca A Lotta.;George D Yancopoulos.;Goncalo R Abecasis.;Aris Baras.;Charles Paulding.; .
来源: Circulation. 2020年141卷8期624-636页
Alirocumab, an antibody that blocks PCSK9 (proprotein convertase subtilisin/kexin type 9), was associated with reduced major adverse cardiovascular events (MACE) and death in the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab). In this study, higher baseline levels of low-density lipoprotein cholesterol (LDL-C) predicted greater benefit from alirocumab treatment. Recent studies indicate high polygenic risk scores (PRS) for coronary artery disease (CAD) identify individuals at higher risk who derive increased benefit from statins. We performed post hoc analyses to determine whether high PRS for CAD identifies higher-risk individuals, independent of baseline LDL-C and other known risk factors, who might derive greater benefit from alirocumab treatment.
694. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
作者: Deepak L Bhatt.;Michael Miller.;Eliot A Brinton.;Terry A Jacobson.;Ph Gabriel Steg.;Steven B Ketchum.;Ralph T Doyle.;Rebecca A Juliano.;Lixia Jiao.;Craig Granowitz.;Jean-Claude Tardif.;Brian Olshansky.;Mina K Chung.;C Michael Gibson.;Robert P Giugliano.;Matthew J Budoff.;Christie M Ballantyne.; .
来源: Circulation. 2020年141卷5期367-375页
Some trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to determine the degree of benefit of icosapent ethyl in the United States.
695. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.
作者: Michael Szarek.;Ph Gabriel Steg.;Dina DiCenso.;Deepak L Bhatt.;Vera A Bittner.;Andrzej Budaj.;Rafael Diaz.;Shaun G Goodman.;Nina Gotcheva.;J Wouter Jukema.;Robert Pordy.;Matthew T Roe.;Timothée Sourdille.;Harvey D White.;Denis Xavier.;Andreas M Zeiher.;Gregory G Schwartz.
来源: Circ Cardiovasc Qual Outcomes. 2019年12卷11期e005858页
In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coronary syndrome in 18 924 patients. Alirocumab reduced first occurrence of the primary composite end point-coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina-as well as total nonfatal cardiovascular events and all-cause deaths. The present analysis determined whether alirocumab reduced total (first and subsequent) hospitalizations and death and increased days alive and out of hospital (DAOH) and percent DAOH in ODYSSEY OUTCOMES.
696. Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.
作者: Lisa M Schwartz.;Steven Woloshin.;Zhigang Lu.;Kathryn M Ross.;Frazer A Tessema.;Doris Peter.;Aaron S Kesselheim.
来源: Circ Cardiovasc Qual Outcomes. 2019年12卷11期e006073页
Recent court decisions have thrown into question the Food and Drug Administration's rules limiting manufacturer promotion of prescription drugs for unapproved uses. We assessed how providing pro forma disclosures or more descriptive evidence context about the data supporting an off-label claim affected physicians' beliefs about drug efficacy.
697. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
作者: Mathieu Kerneis.;Megan K Yee.;Roxana Mehran.;Tarek Nafee.;Christoph Bode.;Jonathan L Halperin.;Eric D Peterson.;Freek W A Verheugt.;Peter Wildgoose.;Martin van Eickels.;Gregory Y H Lip.;Marc Cohen.;Keith A A Fox.;C Michael Gibson.
来源: Circ Cardiovasc Interv. 2019年12卷11期e008160页
Among stented patients with atrial fibrillation, double therapy with a novel oral anticoagulant plus single antiplatelet therapy (SAPT) reduces bleeding or cardiovascular rehospitalizations compared with a vitamin K antagonist (VKA) based triple therapy regimen. A recent study demonstrated that apixaban based double therapy reduced bleeding compared with VKA based double therapy. However, it remains unknown whether rivaroxaban based double therapy is superior to a VKA based double therapy.
698. HIV Infection Is Associated With Variability in Ventricular Repolarization: The Multicenter AIDS Cohort Study (MACS).
作者: Amir S Heravi.;Lacey H Etzkorn.;Jacek K Urbanek.;Ciprian M Crainiceanu.;Naresh M Punjabi.;Hiroshi Ashikaga.;Todd T Brown.;Matthew J Budoff.;Gypsyamber D'Souza.;Jared W Magnani.;Frank J Palella.;Ronald D Berger.;Katherine C Wu.;Wendy S Post.
来源: Circulation. 2020年141卷3期176-187页
People living with human immunodeficiency virus (HIV+) have greater risk for sudden arrhythmic death than HIV-uninfected (HIV-) individuals. HIV-associated abnormal cardiac repolarization may contribute to this risk. We investigated whether HIV serostatus is associated with ventricular repolarization lability by using the QT variability index (QTVI), defined as a log measure of QT-interval variance indexed to heart rate variance.
699. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
作者: Christopher P Cannon.;Vlado Perkovic.;Rajiv Agarwal.;James Baldassarre.;George Bakris.;David M Charytan.;Dick de Zeeuw.;Robert Edwards.;Tom Greene.;Hiddo J L Heerspink.;Meg J Jardine.;Adeera Levin.;Jing-Wei Li.;Bruce Neal.;Carol Pollock.;David C Wheeler.;Hong Zhang.;Bernard Zinman.;Kenneth W Mahaffey.
来源: Circulation. 2020年141卷5期407-410页 700. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
作者: J Wouter Jukema.;Laurien E Zijlstra.;Deepak L Bhatt.;Vera A Bittner.;Rafael Diaz.;Heinz Drexel.;Shaun G Goodman.;Yong-Un Kim.;Robert Pordy.;Željko Reiner.;Matthew T Roe.;Hung-Fat Tse.;Pablo Carlos Montenegro Valdovinos.;Harvey D White.;Andreas M Zeiher.;Michael Szarek.;Gregory G Schwartz.;Philippe Gabriel Steg.; .
来源: Circulation. 2019年140卷25期2054-2062页
Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic stroke. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, despite intensive statin therapy, targeting LDL-C levels of 25 to 50 mg/dL and avoiding sustained LDL-C <15 mg/dL. This prespecified analysis was designed to assess the effect of alirocumab on ischemic and hemorrhagic stroke. We hypothesized that for patients treated with alirocumab there would be a reduction in risk of ischemic stroke without increasing hemorrhagic stroke, irrespective of baseline LDL-C and of history of cerebrovascular disease.
|